腹腔镜与开腹胃癌根治术在局部进展期胃癌新辅助化疗后的短期和长期结局比较:倾向性评分匹配分析
该回顾性研究通过倾向性评分匹配比较了局部进展期胃癌患者在接受新辅助化疗后行腹腔镜与开腹胃切除术的短期和长期结局。匹配后每组81例,腹腔镜组出血量更少、并发症发生率更低、术后住院时间更短,但手术时间更长;两组3年总生存率和无复发生存率无显著差异。
要点
- 腹腔镜组出血量显著少于开腹组(80 vs. 280 mL,P<0.001)
- 腹腔镜组术后并发症率更低(24.7% vs. 42.0%,P=0.002)
- 两组3年总生存和无复发生存无显著差异
核心结论
- 新辅助化疗后腹腔镜胃切除术短期安全有效,长期肿瘤学结局与开腹手术相当。
主要发现
- 腹腔镜组估计出血量显著低于开腹组[80(50-110)vs. 280(210-320)mL,P<0.001]。
- 腹腔镜组手术时间显著长于开腹组[205(186.5-222.5)vs. 182(170-190)min,P<0.001]。
- 腹腔镜组术后并发症发生率显著低于开腹组(24.7% vs. 42.0%,P=0.002)。
- 腹腔镜组术后住院时间显著短于开腹组[8(7-10)vs. 10(8-11.5)天,P=0.001]。
- 亚组分析显示腹腔镜远端胃切除术患者并发症率低于开腹组(18.8% vs. 38.6%,P=0.034),全胃切除术组无此差异(32.3% vs. 45.9%,P=0.251)。
临床怎么用
- 对于接受新辅助化疗的局部进展期胃癌患者,腹腔镜手术可减少出血、降低并发症并缩短住院时间,且不损害长期生存。
局限性
- 回顾性研究设计可能存在选择偏倚,尽管采用了倾向性评分匹配。
- 样本量有限,亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was performed to evaluate the safety and efficacy of laparoscopic gastrectomy (LG) in patients with locally advanced gastric cancer (LAGC) who received neoadjuvant chemotherapy (NACT). METHODS: We retrospectively analyzed patients who underwent gastrectomy for LAGC (cT2-4aN+M0) after NACT from January 2015 to December 2019. The patients were divided into a LG group and an open gastrectomy (OG) group. The short- and long-term outcomes in both groups were examined following propensity score matching. RESULTS: We retrospectively reviewed 288 patients with LAGC who underwent gastrectomy following NACT. Of these 288 patients, 218 were enrolled; after 1:1 propensity score matching, each group comprised 81 patients. The LG group had significantly lower estimated blood loss than the OG group [80 (50-110) vs. 280 (210-320) mL, P < 0.001) but a longer operation time [205 (186.5-222.5) vs. 182 (170-190) min, P < 0.001], a lower postoperative complication rate (24.7% vs. 42.0%, P = 0.002), and a shorter postoperative hospitalization period [8 (7-10) vs. 10 (8-11.5) days, P = 0.001]. Subgroup analysis revealed that patients who underwent laparoscopic distal gastrectomy had a lower rate of postoperative complications than patients in the OG group (18.8% vs. 38.6%, P = 0.034); however, such a pattern was not seen in patients who underwent total gastrectomy (32.3% vs. 45.9%, P = 0.251). The 3-year matched cohort analysis showed no significant difference in overall survival or recurrence-free survival (log-rank P = 0.816 and P = 0.726, respectively) (71.3% and 65.0% in OG vs. 69.1% and 61.7% in LG, respectively). CONCLUSION: In the short term, LG following NACT is safer and more effective than OG. However, the long-term results are comparable.
引用
- Zhong H, Liu X, Tian Y, et al. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis. Surg Endosc. 2023. PMID: 37072637. doi:10.1007/s00464-023-10052-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。